Recruiting

Finerenone for IgA-Nephropathy Treatment Trial

Study Aim

This trial is investigating whether finerenone can improve kidney function in patients with IgA-Nephropathy, a kidney disorder, by measuring changes in albuminuria levels.

What is being tested

Finerenone

Drug

Who is being recruted

Urogenital Diseases+8

+ Autoimmune Diseases

+ Female Urogenital Diseases and Pregnancy Complications

Over 18 Years

+13 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Treatment Study

Interventional

Study Start: May 2025

See protocol details

Summary

Principal SponsorBotkin Hospital

Study ContactEvgeny Shytov, PhDMore contacts

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Study start date: May 21, 2025

Actual date on which the first participant was enrolled.

IgA nephropathy is a common kidney condition known for its poor outlook when persistent albuminuria is present. This study focuses on the drug finerenone, which has shown promise in lowering albumin levels in people with chronic kidney disease (CKD) and type 2 diabetes. The trial aims to explore finerenone's potential benefits for patients with IgA nephropathy, a type of non-diabetic kidney disease. By examining its effects beyond standard treatments, the study hopes to determine if finerenone can slow down the progression of kidney damage in these patients. Participants in this study will receive finerenone in addition to their regular treatment. Researchers will monitor for any side effects and assess the drug's ability to protect the kidneys. The study does not specify the exact methods of finerenone administration, but its results will be measured by observing changes in kidney function and the occurrence of any adverse events. This could lead to new insights into managing IgA nephropathy and improving outcomes for those affected.

Official TitleFinerenone in Patients With IgA-nephropathy: Prospective Interventional Trial

NCT07056595

Principal SponsorBotkin Hospital

Study ContactEvgeny Shytov, PhDMore contacts

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

30 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Conditions

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesAutoimmune DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsGlomerulonephritisGlomerulonephritis, IGAImmune System DiseasesKidney DiseasesNephritisUrologic DiseasesFemale Urogenital DiseasesMale Urogenital Diseases

Criteria

4 inclusion criteria required to participate

Adults (> 18 years) with the primary IgAN diagnosed by kidney biopsy;

Treatment with stable doses of iRAS or/and iSGLT2 inhibitors for at least 3 months prior inclusion into the trial;

Blood pressure < 140/90 mm Hg

24-hour urinary albumin excretion > 300 mg

9 exclusion criteria prevent from participating

Kidney transplantation in medical history

Chronic hepatic disease, including hepatitis, malignant tumor, active malignancy;

Heart failure with ejection fraction <40%;

Acute myocardial infarction and/or stroke less then 3 months before including in trial;

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.

Treatment Groups

Study Objectives

3 intervention groups are designated in this study

This study does not include a placebo group

Treatment Groups

Group I

Experimental

Group II

Experimental

Group III

Experimental

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

Botkin Hospital

Moscow, RussiaOpen Botkin Hospital in Google Maps

Recruiting

One Study Center